Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 13, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Sept. 13, 2024 -- Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2 diabetes who have not received insulin, according to a study published online Sept. 10 in the New England Journal of Medicine to coincide with the annual meeting of the European Association for the Study of Diabetes, held from from Sept. 9 to 13 in Madrid.

Carol Wysham, M.D., from the MultiCare Rockwood Center for Diabetes and Endocrinology in Spokane, Washington, and colleagues conducted a 52-week, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin. Participants were randomly assigned to receive efsitora (466 patients) or degludec (462 patients).

The researchers found that from baseline to week 52, there was a decrease in the mean glycated hemoglobin level from 8.21 to 6.97 percent with efsitora and from 8.24 to 7.05 percent with degludec (estimated treatment difference, 0.09 percentage points), with the results demonstrating noninferiority. In participants using and not using glucagon like peptide-1 receptor agonists, efsitora was noninferior to degludec with respect to change in the glycated hemoglobin level. The percentage of time that the glucose level was within target range was 64.3 and 61.2 percent with efsitora and degludec, respectively (estimated treatment difference, 3.1 percentage points). The rate of combined clinically significant or severe hypoglycemia was 0.58 and 0.45 events per participant-year of exposure with efsitora and degludec, respectively (estimated rate ratio, 1.30).

"Noninferiority to once-daily degludec with respect to the change in the glycated hemoglobin level from baseline to week 52 was shown," the authors write.

Several authors disclosed ties to the pharmaceutical industry, including Eli Lilly, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-09-14 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords